Advanced hypopharyngeal carcinoma treatment results according to treatment modalities

被引:11
作者
Kim, S
Wu, HG
Heo, DS
Kim, KH
Sung, MW
Park, CI
机构
[1] Seoul Natl Univ, Coll Med, Dept Therapeut Radiol, Chongno Gu, Seoul 110744, South Korea
[2] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 151, South Korea
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2001年 / 23卷 / 09期
关键词
hypopharyngeal carcinoma; surgery; radiation; therapy; neoadjuvant chemotherapy;
D O I
10.1002/hed.1101
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. The purpose of this retrospective study is to compare the treatment results of locally advanced hypopharyngeal carcinoma according to treatment modalities. Methods, Seventy-three patients with locally advanced hypopharyngeal carcinoma treated at the Department of Therapeutic Radiology, Seoul National University Hospital, between August 1979 and July 1997 were retrospectively analyzed. Twenty-three patients were treated with radiotherapy (RT) alone, 18 patients were treated with surgery and postoperative RT, and 32 patients were treated with neoadjuvant chemotherapy (CTx) and RT. Median follow-up period was 28 months. Results. The overall 5-year survival rates were 15.7% for the FIT alone group, 46.8% for surgery and postoperative FIT group, and 43.0% for neoadjuvant CTx and RT group, The 5-year disease-free survival rates were 13.9%, 47.4%, and 30.7%, respectively. Surgery and postoperative FIT or neoadjuvant CTx and FIT showed superiority over RT alone in terms of both overall survival and disease-free survival rates. No significant differences were found in overall and disease-free survival rates between the surgery and postoperative FIT group and neoadjuvant CTx and RT group (p = .15, p = .13). In the neoadjuvant CTx and FIT group, 12 patients (38%) retained their larynx more than 5 years, Conclusion. Neoadjuvant CTx and RT is an effective strategy to achieve organ preservation without compromising the survival of patients with locally advanced hypopharyngeal carcinoma. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:713 / 717
页数:5
相关论文
共 50 条
  • [21] Outcomes of surgical versus non-surgical treatment of resectable T4a laryngeal and hypopharyngeal carcinoma
    Thiagarajan, S.
    Gupta, M.
    Sathe, P.
    Gill, G.
    Ghosh-Laskar, S.
    Prabhash, K.
    Chaukar, D.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2022, 136 (11) : 1087 - 1095
  • [23] Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study
    Modh, Ankit
    Rimner, Andreas
    Allen, Pamela K.
    Greenfield, Brad
    Marom, Edith M.
    Rice, David
    Huang, James
    Rosenzweig, Kenneth E.
    Komaki, Ritsuko
    Gomez, Daniel R.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (02): : 120 - 125
  • [24] Oncologic outcome of hypopharyngeal carcinoma treated with different modalities at 2 different university hospitals
    Bussu, Francesco
    Mura, Federica
    Micciche, Francesco
    Bertino, Giulia
    Occhini, Antonio
    Almadori, Giovanni
    Galli, Jacopo
    Pandolfini, Manlio
    Gallus, Roberto
    Autorino, Rosa
    Guidi, Maria Lavinia
    Dinapoli, Nicola
    Valentini, Vincenzo
    Paludetti, Gaetano
    Benazzo, Marco
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (04): : 606 - 612
  • [25] Emerging treatment modalities for advanced pancreatic neuroendocrine tumors
    Sindoni, Alessandro
    Fama, Fausto
    Gioffre-Florio, Maria
    Baldari, Sergio
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (04): : 563 - 564
  • [26] Salvage vs. Primary Total Laryngectomy in Patients with Locally Advanced Laryngeal or Hypopharyngeal Carcinoma: Oncologic Outcomes and Their Predictive Factors
    Shoushtari, Shahin Tahan
    Gal, Jocelyn
    Chamorey, Emmanuel
    Schiappa, Renaud
    Dassonville, Olivier
    Poissonnet, Gilles
    Aloi, Deborah
    Barret, Mederic
    Safta, Inga
    Saada, Esma
    Sudaka, Anne
    Culie, Dorian
    Bozec, Alexandre
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [27] Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
    Furubayashi, Nobuki
    Mochida, Manabu
    Kijima, Atsuhiro
    Fujimoto, Yushi
    Nakamura, Motonobu
    Negishi, Takahito
    IN VIVO, 2025, 39 (02): : 976 - 987
  • [28] Treatment of hypopharyngeal carcinoma: analysis of nationwide study in the Netherlands over a 10-year period
    Sewnaik, A
    Hoorweg, JJ
    Knegt, PP
    Wieringa, MH
    Beek, JMH
    Kerrebijn, JDF
    CLINICAL OTOLARYNGOLOGY, 2005, 30 (01): : 52 - 57
  • [29] Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study
    Huang, Tian-Qiao
    Wang, Ru
    Fang, Ju-Gao
    He, Shi-Zhi
    Zhong, Qi
    Hou, Li-Zhen
    Ma, Hong-Zhi
    Chen, Xiao-Hong
    Chen, Xue-Jun
    Li, Ping-Dong
    Feng, Ling
    Shi, Qian
    Lian, Meng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [30] A case of peritoneal metastasis during treatment for hypopharyngeal squamous cell carcinoma
    Wakasaki, Takahiro
    Omori, Hirofumi
    Sueyoshi, Shintaro
    Rikimaru, Fumihide
    Toh, Satoshi
    Taguchi, Kenichi
    Higaki, Yuichiro
    Morita, Masaru
    Masuda, Muneyuki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14